Serum immunoglobulin E and Interleukin-17 levels in patients with chronic plaque psoriasis: A case-control study.

BACKGROUND: Psoriasis is a skin disorder mainly mediated by T helper (Th)-1 and Th-17 cells. Recently, high serum immunoglobulin (Ig)-E levels were detected in psoriatic patients. The etiopathogenesis of IgE overproduction in psoriatic patients is still unknown, but IL-17 has been suggested to be responsible for this abnormality. OBJECTIVE: To compare levels of IgE and IL-17 in the sera of patients with chronic plaque psoriasis (CPP) to healthy subjects. METHODS: This study included 40 patients with CPP and 40 age- and sex-matched healthy individuals. Serum IgE and IL-17 concentrations were measured using the enzyme-linked immunosorbent assay (ELISA) technique. RESULTS: Levels of IgE and IL-17 were significantly higher in the sera of psoriatic patients than in controls (p = 0.001 and 0.024, respectively). Psoriatic patients with abnormally high serum IgE levels had higher serum IL-17 levels than those with normal serum IgE levels, but the difference was statistically insignificant (p = 0.080). Furthermore, no significant correlation was found between serum IgE and IL-17 concentrations in psoriatic patients (p = 0.385). CONCLUSIONS: It is possible that IgE and IL-17 interact in psoriasis pathogenesis; however, this was not evident in the current study, possibly due to the small sample size. Therefore, other potential causes of elevated IgE levels in psoriatic patients should be investigated. Moreover, the interaction between IgE and IL-17 should be investigated in patients with other clinical variants of psoriasis.

Hepatitis C virus infection could be a risk factor for adult-onset vitiligo in Egyptian patients: A cross-sectional study.

BACKGROUND: Vitiligo is a common skin disorder resulting from the destruction of melanocytes. Hepatitis C virus (HCV) infection has been linked to a variety of extrahepatic manifestations, including skin diseases. AIM: To measure the prevalence of HCV-seroreactivity among vitiligo patients. METHODS: This cross-sectional study included 108 vitiligo patients. Serum anti-HCV antibodies were detected by chemiluminescence immunoassay. RESULTS: Eighteen patients (16.7%) out of 108 were HCV-reactive; all of them had adult-onset vitiligo. They represented approximately 34.6% of the total patients with adult-onset vitiligo (52 patients). On the contrary, all patients with childhood-onset vitiligo were HCV-non-reactive. Moreover, adult-onset vitiligo was significantly associated with HCV-seroreactivity (p < .001). Also, there was a significant difference between HCV-reactive and HCV-non-reactive vitiligo patients regarding the age of patients and their ages at the onset of vitiligo (p < .001). CONCLUSIONS: HCV may be the triggering factor for adult-onset vitiligo, particularly in regions with a high prevalence of HCV. Therefore, patients with adult-onset vitiligo, rather than childhood-onset disease, should be screened for associated HCV infection in HCV-endemic regions.

Complement component 3c and tumor necrosis factor-α systemic assessment after Candida antigen immunotherapy in cutaneous warts.

BACKGROUND: Cutaneous warts are the commonest benign lesion produced by human papillomavirus. Lesions often regress spontaneously yet have a high rate of recurrence. They impair patients' quality of life and carry the potential risk of cancer. Nowadays, Candida antigen immunotherapy has become an encouraging therapeutic modality for warts. We tried to assess the role of the complement pathway and T helper 1 immune response in clinical response to Candida antigen immunotherapy via complement component 3c (C3c) and tumor necrosis factor (TNF)-α, respectively. METHODS: A total of 44 patients with cutaneous warts were enrolled in the study. Patients were injected with Candida antigen at 2-week interval until complete clearance of the lesion or for a maximum of 5 sessions. Blood samples were collected before initiation and after completion of immunotherapy. C3 and C4 were measured using an automated turbidimetric method. Mannose-binding lectin (MBL), C3c, and TNF-α were measured using enzyme-linked immune sorbent assay. RESULTS: A total of 56.4%, 17.9%, and 25.7% of the patients showed complete, partial, and no response to immunotherapy, respectively. Lesions on the dorsum of the foot and sole showed significant clearance (p value = 0.037). All patients had no deficient C3, C4, and MBL serum levels. C3c and TNF-α serum levels were significantly higher in non-responder group (p value < 0.001 and < 0.001, respectively). C3c and TNF-α serum levels were strongly correlated in all the studied patients (r = 0.8, p value < 0.001). CONCLUSIONS: Candida antigen immunotherapy is an effective therapeutic modality for cutaneous warts. C3c and TNF-α serum levels were higher in patients who failed to respond to immunotherapy. CLINICAL TRIAL REGISTRY NUMBER: NCT04399577 , May 2020 "retrospectively registered".